Single-Ingredient Series · Evidence Review
An evidence-based review of magnesium glycinate chemistry, absorption, sleep and health outcomes, elemental dosing, safety, and quality.
Executive summary
What the evidence says
Magnesium is a cofactor in over 300 enzymatic reactions and the fourth most abundant mineral in the human body. Despite its biological centrality, approximately 48% of Americans consume less than the estimated average requirement from dietary sources alone.1,2 Magnesium glycinate — magnesium chelated to glycine — is absorbed via two intestinal pathways: passive paracellular diffusion and active uptake through amino acid transporters, making it less dependent on gastric acid than inorganic forms and substantially reducing GI side effects. The glycine carrier itself has independent roles as an inhibitory neurotransmitter with sleep-supportive effects. The strongest human evidence supports: a modest but statistically significant improvement in sleep quality with the bisglycinate form specifically (one dedicated RCT, n=155, Cohen's d=0.20, p=0.049, 2025);6 a class-level blood pressure reduction (~2.8/2.1 mmHg; 38 RCTs, n=2,709);15 and a reduction in migraine attack frequency (~2.5 attacks/month; 22 trials).18 Evidence for everyday stress response is directionally positive but methodologically limited. Mood data are conflicting. Bone support is preliminary; muscle cramp benefit is established in pregnancy but not in the general adult population. Product: Magnesium Glycinate Capsules — Pacific Formulations Single-Ingredient Series.
What Is Magnesium Glycinate?
Magnesium (Mg²⁺) is an essential divalent cation required as a cofactor in over 300 enzymatic reactions. 1
The adult body contains approximately 25 grams of magnesium: 50–60% resides in bone, with the
remainder distributed across soft tissues, primarily intracellular muscle. Serum magnesium — the fraction most often measured clinically — represents less than 1% of total body magnesium and is not a sensitive indicator of intracellular status. Despite its biological importance, analysis of NHANES data found that approximately 48% of Americans consume less than the Estimated Average Requirement (EAR) from food.2 Common dietary sources
include dark leafy greens, nuts, seeds, whole grains, and legumes — all of which are underrepresented in processed Western diets.
The Glycinate (Bisglycinate) Form
Magnesium glycinate is produced by chelating magnesium to glycine, a conditionally essential amino acid. In the scientific literature, "magnesium glycinate," "magnesium bisglycinate," and "magnesium diglycinate" refer to the same compound: one magnesium ion chelated to two glycine molecules (1:2 ratio). This document uses both terms interchangeably as the literature does. The chelation is stable across a range of gastric pH values, protecting the mineral through stomach transit. Critically, magnesium glycinate can be absorbed via intestinal amino acid and dipeptide transporters — in addition to the passive paracellular route used by inorganic forms — making it effective even when gastric acid production is reduced (achlorhydria, proton pump inhibitor use, older age).3
Mechanism of Action
Enzymatic Cofactor (300+ Reactions)
Magnesium is required for all reactions involving ATP, since the biologically active form is Mg-ATP²⁻. This includes glycolysis, oxidative phosphorylation, DNA and RNA synthesis, protein synthesis, and activation of sodium-potassium ATPase. Magnesium acts as a structural cofactor for more than 300 enzyme classes.1
NMDA Receptor Voltage-Dependent Block
At resting membrane potentials, Mg²⁺ occupies the pore of NMDA-type glutamate receptor channels, preventing excessive calcium influx. This "Mg block" is critical for synaptic plasticity, learning, and protection against excitotoxicity.1
HPA Axis and Stress Physiology
Magnesium potentiates GABA-A receptor activity and modulates the hypothalamic-pituitary-adrenal (HPA) axis. Hypomagnesemia is associated with heightened HPA reactivity and elevated cortisol responses to stress, suggesting a bidirectional relationship between magnesium status and stress physiology.11
Vascular Smooth Muscle Relaxation
Magnesium functions as a physiological calcium channel antagonist in vascular smooth muscle. By competing with calcium at voltage-gated channels, adequate magnesium promotes vasodilation and reduced peripheral vascular resistance — a mechanism underlying its blood pressure effects.15,16
Melatonin Synthesis
Magnesium is a cofactor in the conversion of serotonin to melatonin via arylalkylamine Nacetyltransferase, directly linking magnesium status to circadian rhythm regulation and sleep onset latency.6
Bone Metabolism
Magnesium ions occupy hydroxyapatite lattice sites in bone, influencing crystal size and structural integrity. Magnesium also modulates parathyroid hormone (PTH) secretion and vitamin D metabolism — both central to calcium homeostasis and bone remodeling.21,22
Glycine: Independent Neurotransmitter Effects
Glycine, the chelating amino acid, is an inhibitory neurotransmitter at glycine receptors in the spinal cord and brainstem, and a co-agonist at the NMDA receptor glycine site. Oral glycine supplementation independently reduces sleep onset latency, increases slow-wave sleep, and improves subjective sleep quality in crossover trials.9,10 This suggests the glycinate chelate may produce additive sleep benefit through both the magnesium and glycine fractions.
Evidence Review
Bioavailability: Why the Chelate Form Matters
STRONGA systematic review of human bioavailability studies across magnesium supplement forms found that organic forms — glycinate, citrate, malate — consistently demonstrate superior fractional absorption compared with inorganic forms (oxide, carbonate).5 The glycinate and citrate forms showed the highest retention indices. Walker et al. (2003) — Crossover RCT, n=46. Magnesium citrate and amino acid chelate vs. magnesium oxide at equivalent elemental doses. Urinary magnesium excretion (index of absorption) was significantly higher with organic forms (p=0.033).4
Schuette et al. (1994) — Human absorption study, ileal resection patients. Magnesium diglycinate chelate absorbed via intestinal dipeptide transport systems, maintaining absorption efficiency even under conditions of reduced gastric acid — unlike magnesium oxide.3
The structural basis for the bioavailability advantage is the dual absorption mechanism: passive paracellular diffusion and active amino acid/dipeptide transporter uptake. The GI tolerability advantage follows directly: chelated magnesium is absorbed before reaching the large intestine, substantially reducing the osmotic laxation that drives GI side effects with inorganic forms.3,5
Sleep Quality
MODERATESchuster, Oster & Becker (2025) — Placebo-controlled RCT, n=155. Magnesium bisglycinate at 250 mg elemental Mg nightly for 4 weeks. Insomnia Severity Index (ISI) improved significantly more in the Mg bisglycinate group vs. placebo (mean difference −1.7 points, Cohen's d=0.20, p=0.049). Subgroup analysis: the effect was concentrated in participants with low habitual dietary magnesium intake. Limitation: modest effect size; sleep architecture not confirmed by polysomnography.6
Mah & Pitre (2021) — Systematic review and meta-analysis, 3 RCTs, n=151 (older adults). Magnesium supplementation reduced sleep onset latency by 17.36 minutes (p=0.0006) and increased sleep time by 16.03 minutes. Evidence quality rated low to very low by the authors.7
Rawji et al. (2024) — Systematic review, 8 sleep studies. Five of 8 trials showed significant sleep improvements with magnesium. Heterogeneity limited pooled conclusions.8
The glycine component adds independent evidence: two crossover trials (Yamadera et al., 2007; Bannai & Kawai, 2012) found that 3 g oral glycine before bed reduced sleep onset latency, increased slow-wave sleep, and improved subjective quality versus placebo.9,10 These parallel mechanistic pathways distinguish the glycinate form from other magnesium chelates. Strength assessment: directionally consistent across studies; the only form-specific bisglycinate RCT shows a real but modest effect (d=0.20). Glycine-component research provides mechanistic depth. Overall: Moderate.
Everyday Stress Response
PRELIMINARYBoyle, Lawton & Dye (2017) — Systematic review, 18 studies. Generally positive findings for magnesium supplementation in anxiety-vulnerable populations (PMS, mild anxiety, stress-induced physiological changes). Most studies were low quality.11
Rawji et al. (2024) — Systematic review. Five of 7 anxiety-related studies showed significant improvement with magnesium.8
No RCT has specifically tested magnesium bisglycinate or glycinate for stress as a primary endpoint with adequate power. The mechanism via HPA axis modulation and NMDA gating is plausible but not confirmed in a form-specific trial. Claims should be qualified accordingly.
Mood
CONFLICTINGMoabedi et al. (2023) — Systematic review and meta-analysis, 7 RCTs. Significant antidepressant signal (SMD −0.919, p=0.001). High heterogeneity (I²=75.6%) substantially limits interpretability.12
Tarleton et al. (2017) — Open-label RCT, n=126. 248 mg elemental Mg from magnesium chloride daily for 6 weeks: PHQ-9 scores improved by 6.0 points, GAD-7 by 4.5 points. Significant limitation: no placebo control.13
Phelan et al. (2018) — Systematic review and meta-analysis of placebo-controlled trials only. No significant effect on depression (g=−0.21, not significant).14
Two meta-analyses reach opposite conclusions depending on inclusion criteria. No placebo-controlled bisglycinate-specific RCT exists for mood. Pacific Formulations does not make mood claims for this product.
Blood Pressure Support
MODERATEArgeros et al. (2025) — Systematic review and meta-analysis, 38 RCTs, n=2,709. Magnesium supplementation significantly reduced SBP by 2.81 mmHg and DBP by 2.05 mmHg. Effects were larger in hypertensive subjects and those with dietary magnesium deficiency.15
Zhang et al. (2016) — Meta-analysis, 34 RCTs, n=2,028. SBP −2.00 mmHg, DBP −1.78 mmHg with magnesium supplementation.16
Alharran et al. (2024) — Umbrella meta-analysis, 10 prior meta-analyses, n=8,610. Consistent BP-lowering effect across all included analyses; greater magnitude at doses ≥400 mg elemental Mg/day.17
The FDA has issued a qualified health claim for magnesium and blood pressure, noting the evidence is "inconsistent and inconclusive" at the population level — meaning the effect is replicated but varies by individual magnesium status. No glycinate-specific BP RCT exists; the evidence base is for the magnesium class.
Migraine Frequency
MODERATEYang et al. (2024) — Systematic review and meta-analysis, 22 trials. Magnesium supplementation significantly reduced migraine attack frequency (MD −2.51 attacks/month), severity (MD −0.88), and monthly headache days (MD −1.66).18
Chiu et al. (2016) — Meta-analysis of oral and IV magnesium RCTs. Significant reductions in migraine frequency and intensity with oral supplementation.19
The American Academy of Neurology and American Headache Society classify magnesium as "probably effective" for migraine prevention (Level B evidence).20 Most migraine trials used magnesium oxide or citrate; the glycinate form has not been specifically evaluated. The AAN guideline supports the class, not a specific form.
Bone Health
PRELIMINARYSari & Darma (2025) — Meta-analysis, 9 RCTs, n=825. Magnesium supplementation significantly reduced alkaline phosphatase (SMD −0.35) and osteocalcin (SMD −0.29) — bone turnover markers — and improved quality of life. Fracture risk reduction (RR=0.72) showed a non-significant trend (p=0.06).21
Farsinejad-Marj et al. (2016) — Systematic review and meta-analysis, 12 observational studies. Positive but marginal correlations between dietary magnesium intake and BMD at total hip (r=0.16) and femoral neck (r=0.14).22
NIH ODS states: "Diets that provide recommended levels of magnesium enhance bone health, but further research is needed to elucidate the role of magnesium in preventing osteoporosis."1 Bone turnover biomarker improvement is replicated; fracture reduction is not yet confirmed in powered trials.
Muscle Cramps
LIMITEDSystematic review (2025), 10 Mg RCTs for muscle cramp endpoints. Magnesium was effective for pregnancy-related leg cramps (RR=1.35, p=0.02) but not for general adult leg cramps (MD −0.42 episodes/week, p=0.26, not significant).23
The evidence does not support magnesium supplementation for muscle cramps in the general adult population. The pregnancy-specific effect may reflect gestational magnesium depletion not present in most adults.
Dosing & Usage
Elemental vs. Compound Weight
The clinically relevant metric is elemental magnesium, not total compound mass. Magnesium bisglycinate contains approximately 14% elemental magnesium by molecular weight (Mg atomic weight 24.3; bisglycinate MW ~172.4). A serving of 500 mg magnesium bisglycinate delivers approximately 70 mg elemental magnesium. Delivering 300 mg elemental Mg requires approximately 2,143 mg of the compound.
Labels must state elemental Mg content. Consumers and healthcare providers should compare products on elemental Mg per serving, not compound weight.
Evidence-Based Dosing Range
| Outcome area | Dose range (elemental Mg) | Duration in evidence |
|---|---|---|
| Sleep quality (bisglycinate-specific) | 250 mg/day | 4 weeks |
| Blood pressure | 300-600 mg/day | 1-6 months across multiple meta-analyses |
| Migraine prevention | 400-600 mg/day | 3-6 months across multiple RCTs |
| Bone biomarkers | 200-400 mg/day | 3-12 months |
Pacific Formulations Product Dose
Pacific Formulations' Magnesium Glycinate Capsules provide 200 mg elemental magnesium per serving (Supplement Facts: Magnesium [as magnesium glycinate] 200 mg). This positions the product at a well-tolerated entry dose — below the NIH supplement UL of 350 mg/day — and within the lower end of the clinical range studied for sleep quality (250 mg in Schuster 2025) and blood pressure support (300–600 mg across meta-analyses). Individuals whose healthcare provider recommends a higher elemental dose can take additional servings while remaining within the UL; those seeking to replicate the blood pressure or migraine trial dose range should discuss serving adjustments with a qualified healthcare professional.
Timing
For sleep-related outcomes, evening or pre-bedtime administration aligns with the melatonin synthesis mechanism and is the timing used in the Schuster 2025 trial.6 For blood pressure and general status correction, consistent daily timing is sufficient — morning or evening, with or without food.
Who May Benefit Most
Clinical data consistently show larger effects in individuals with sub-optimal dietary magnesium intake. 6,15
Higher-risk groups include: adults over 50 (reduced absorption efficiency), individuals using PPIs
long-term, those with type 2 diabetes or insulin resistance (urinary Mg losses), and people consuming primarily processed foods.
Safety & Tolerability
Tolerable Upper Intake Level
The NIH Tolerable Upper Intake Level (UL) for supplemental magnesium (non-food sources) is 350 mg elemental Mg/day for adults aged 19+.1 Amounts above the UL from supplements may cause diarrhea, nausea, and abdominal cramping. This UL applies to supplemental sources only; there is no UL for food-source magnesium.
GI Tolerability
Magnesium glycinate's GI tolerability is consistently superior to inorganic forms. Osmotic laxation — the primary driver of GI complaints with magnesium supplements — is substantially reduced when absorption occurs via amino acid transporters rather than passive colonic diffusion.3,5
Drug Interactions
| Drug class | Interaction | Management |
|---|---|---|
| Tetracycline / fluoroquinolone antibiotics | Magnesium reduces antibiotic absorption | Separate doses by at least 2 hours |
| Bisphosphonates (for example, alendronate) | Magnesium reduces bisphosphonate absorption | Separate doses by at least 2 hours |
| Proton pump inhibitors (long-term use) | May cause magnesium depletion over months | Monitor; supplementation may be warranted |
| Loop / thiazide diuretics | Increase urinary magnesium losses | Monitor serum magnesium; consider supplementation |
| Calcineurin inhibitors (for example, tacrolimus) | Risk of hypomagnesemia | Consult the prescriber before supplementing |
| Digoxin | Low magnesium increases digitalis-toxicity risk | Maintain adequate magnesium status |
Contraindications
Impaired renal function (GFR <30 mL/min): kidneys regulate magnesium excretion, and reduced clearance creates hypermagnesemia risk. Individuals with kidney disease should use supplemental magnesium only under medical supervision.1
Quality & Sourcing
What Distinguishes High-Quality Magnesium Glycinate
1. Verified elemental content. The label must state both compound weight and elemental Mg. Thirdparty testing should confirm the label claim is accurate to within ±5%.
2. True chelate integrity. A genuine magnesium bisglycinate chelate (1:2 Mg:glycine ratio) should be confirmed by the manufacturer via chelation index or HPLC analysis. Some products blend magnesium glycinate with magnesium oxide and label the result as a "glycinate complex" — this significantly reduces the bioavailability and tolerability advantage.
3. Minimal excipients. A single-ingredient capsule should contain only the active compound and pharmaceutical-grade capsule components (e.g., HPMC for vegetarian capsules).
4. Third-party testing. A Certificate of Analysis (CoA) from an ISO 17025-accredited or NSF-certified laboratory verifying identity, purity, and absence of heavy metals and microbial contaminants.
Pacific Formulations Position
Pacific Formulations' Magnesium Glycinate capsules contain a verified magnesium bisglycinate chelate at a dose calibrated to deliver elemental magnesium within the evidence-based range. The single-ingredient capsule format eliminates confounders, enabling users to track their individual response — meeting the standard demanded by health professionals and informed consumers who require clean, traceable supplementation.
Conclusion
Magnesium glycinate (bisglycinate) delivers a well-tolerated, highly bioavailable form of an essential mineral that is chronically insufficient in modern diets. The chelated glycinate form's dual absorption mechanism — passive diffusion plus amino acid transporter uptake — provides a measurable bioavailability advantage over inorganic forms and is associated with substantially better GI tolerability. The evidence base is strongest for sleep quality improvement (moderate evidence; one dedicated bisglycinate RCT showing real effect; glycine component adds mechanistic depth), class-level blood pressure reduction (~2–3 mmHg; highly replicated across 38 RCTs), and reduction in migraine attack frequency (~2.5 attacks/month; 22 trials; AAN Level B). Everyday stress response support is directionally consistent but requires better-powered form-specific research. Mood data are conflicting and should not be claimed. Bone health benefit is emerging. Muscle cramp reduction is established in pregnancy only. Pacific Formulations presents this document as a working summary of the current scientific evidence — subject to update as research develops — rather than a sales instrument.
References
Sources
- National Institutes of Health, Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals. Updated January 2, 2026. https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/
- Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutr Rev. 2012;70(3):153–164. doi:10.1111/j.1753-4887.2011.00465.x. PMID:22364157.
- Schuette SA, Lashner BA, Janghorbani M. Bioavailability of magnesium diglycinate vs magnesium oxide in patients with ileal resection. JPEN J Parenter Enteral Nutr. 1994;18(5):430–435. doi:10.1177/0148607194018005430. PMID:8080913.
- Walker AF, Marakis G, Christie S, Byng M. Mg citrate found more bioavailable than other Mg preparations in a randomised, double-blind study. Magnes Res. 2003;16(3):183–191. PMID:14596323.
- Pardo MR, Garicano Vilar E, San Mauro Martín I, Camina Martín MA. Bioavailability of magnesium food supplements: A systematic review. Nutrition. 2021;89:111294. doi:10.1016/j.nut.2021.111294.
- Schuster J, Oster M, Becker N. Magnesium bisglycinate supplementation improves sleep quality in healthy middle-aged individuals: a double-blind, placebo-controlled randomised trial. Nat Sci Sleep. 2025;17:935–950. PMC12412596.
- Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a systematic review & meta-analysis. BMC Complement Med Ther. 2021;21(1):125. doi:10.1186/s12906-021-03297-z. PMID:33865376.
- Rawji A, Peltier MR, Mourtzanakis K, et al. Examining the Effects of Supplemental Magnesium on Self-Reported Anxiety and Sleep Quality: A Systematic Review. Cureus. 2024;16(4):e59317. doi:10.7759/cureus.59317. PMID:38817505.
- Yamadera W, Inagawa K, Chiba S, Bannai M, Takahashi M, Nakayama K. Glycine ingestion improves subjective sleep quality in human volunteers, correlating with polysomnographic changes. Sleep Biol Rhythms. 2007;5(2):126–131. doi:10.1111/j.14798425.2007.00262.x.
- Bannai M, Kawai N. New therapeutic strategy for amino acid medicine: glycine improves the quality of sleep. J Pharmacol Sci. 2012;118(2):145–148. doi:10.1254/jphs.11R13FM.
- Boyle NB, Lawton C, Dye L. The Effects of Magnesium Supplementation on Subjective Anxiety and Stress — A Systematic Review. Nutrients. 2017;9(5):429. doi:10.3390/nu9050429. PMID:28445426.
- Moabedi M, Aliakbari M, Erfanian S, Milajerdi A. Magnesium supplementation beneficially affects depression in adults with depressive disorder: a systematic review and meta-analysis. Front Psychiatry. 2023;14:1333261. doi:10.3389/fpsyt.2023.1333261. PMID:38213402.
- Tarleton EK, Littenberg B, MacLean CD, Kennedy AG, Daley C. Role of magnesium supplementation in the treatment of depression: A randomized clinical trial. PLoS One. 2017;12(6):e0180067. doi:10.1371/journal.pone.0180067. PMID:28654669.
- Phelan D, Molero P, Martínez-González MA, Molero J. Magnesium and mood disorders: systematic review and meta-analysis. BJPsych Open. 2018;4(4):167–179. doi:10.1192/bjo.2018.22.
- Argeros Z, Sanna B, De Pietri S, et al. Effects of Magnesium Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2025. doi:10.1161/HYPERTENSIONAHA.124.24401. PMID:41000008.
- Zhang X, Li Y, Del Gobbo LC, et al. Effects of Magnesium Supplementation on Blood Pressure: A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials. Hypertension. 2016;68(2):324–333. doi:10.1161/HYPERTENSIONAHA.116.07664. PMID:27402922.
- Alharran AA, Bousfield H, Farwell D, Soltero S, Steinberg FM, Bakhach M. The Effect of Magnesium Supplementation on Hypertension: An Umbrella Meta-Analysis. Curr Ther Res Clin Exp. 2024;101:100755. doi:10.1016/j.curtheres.2024.100755.
- Yang M, Yan Y, Yin X, et al. Dietary supplements for the prevention and treatment of migraine: A meta-analysis of randomized controlled trials. Neurol Sci. 2024;45(12):5741–5751. doi:10.1007/s10072-024-07650-3. PMID:39404918.
- Chiu HY, Yeh TH, Huang YC, Chen PY. Effects of Intravenous and Oral Magnesium on Reducing Migraine: A Meta-analysis of Randomized Controlled Trials. Pain Physician. 2016;19(1):E97–112. PMID:26752497.
- Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology. 2012;78(17):1346–1353. doi:10.1212/WNL.0b013e3182535d60. PMID:22529203.
- Sari MI, Darma S. Effect of magnesium supplementation on bone turnover markers and quality of life: A meta-analysis of randomized controlled trials. Bioscientia Medicina. 2025;9(4). doi:10.37275/bsm.v9i4.1249.
- Farsinejad-Marj M, Saneei P, Esmaillzadeh A. Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016;27(4):1389–1399. doi:10.1007/s00198-015-3400-y.
- Gröber U, Werner T, Vormann J, Kisters K. Myth or Reality — Electrolytes and Muscle Cramps: A Narrative Review with Systematic Methodology. Nutrients. 2025. PMC12994056.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
This article is intended for informational and educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional before beginning any supplementation program.
© 2026 Pacific Formulations. Prepared June 2026.